Patients with progressive disease after one first-line platinum-based chemotherapy are randomised 2:1 to oral afatinib ( starting dose 40 mg once daily ) or IV methotrexate ( starting dose 40 mg/m ( 2 ) once weekly ) administered as monotherapy with best supportive care until progression or intolerable adverse events .